The Lancet· Yasaman Vali, Kristy Wonders, Jenny Lee, Guruprasad P Aithal, Rocio Aller, Michael E D Allison, Johanna Arola, Jesus M Banales, Vanesa Bernal-Monterde, Annalisa Berzigotti, Jérôme Boursier, Clifford A Brass, Elisabetta Bugianesi, Jose Luis Calleja, Jeremy F Cobbold, Helena Cortez-Pinto, Javier Crespo, Susan Davies, Ann Driessen, Kevin L Duffin, Mattias Ekstedt, Daniel Forton, Céline Fournier-Poizat, Sven Francque, Andreas Geier, Joseph Gogain, Annette S H Gouw, Hannes Hagström, Adriaan G Holleboom, Prodromos Hytiroglou, Morten Karsdal, Carolin Lackner, Diana J Leeming, Luca Miele, George Papatheodoridis, Valerie Paradis, Michael Pavlides, Juan M Pericàs, Salvatore Petta, Vlad Ratziu, Manuel Romero-Gomez, Jörn M Schattenberg, Detlef Schuppan, Rambabu Surabattula, Ana Paula Silva, Mette Skalshøi Kjær, Beate K Straub, Gianluca Svegliati-Baroni, Dina Tiniakos, Maria Manuela Tonini, Richard Torstenson, Luca V C Valenti, Joanne Verheij, Jeremy Magnanensi, Rebeca Mayo, David Wenn, Hannele Yki-Järvinen, Carla Yunis, Patrick M Bossuyt, Quentin M Anstee, LITMUS Investigators·· 29 分钟前AI 评分42
LITMUS 前瞻性多中心诊断准确性研究：代谢功能障碍相关脂肪性肝病中的无创检测
[Articles] Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study
AI 导读
LITMUS 前瞻性多中心诊断准确性研究评估了代谢功能障碍相关脂肪性肝病（MASLD）的无创检测。单一标志物对比组织学检测 at-risk MASH 时性能有限且不稳定，而多标志物组合展现出较大潜力，其中蛋白组学 panel 诊断性能较强。这些发现可支持 MASLD 无创检测策略的选择与实施，并为未来临床指南、监管评估和临床试验设计提供依据。
来源：The Lancet · thelancet.com